- Nature Communications
TG4050
TG4050 as a single agent has the potential to prevent recurrence in head and neck cancer
Peer-reviewed publication in Nature Communications highlights the Phase 1 clinical and translational findings
Article available for the first time on Nature Communications website – Download the Article - Advancing our pipeline
Expanding myvac®
TG4050, Head and neck cancer (adjuvant) – Phase 2 ongoing
TG4070, Non-small cell lung cancer (adjuvant) – Phase 1
.